Member Info for Mulder

Experts think Corbyn has peaked as Labour lose council seats.

Not sold any either. Trading at 11x earnings is cheap for a utility company. Higher oil prices will also help JV that is Spirit Energy. Nuclear plant sale also on the horizon for 2Bn GBP+

Ex-Dividend Thurs 10th May 8.4p/share [Yield 5.5%]

It looks like the shorters are hammering this on account of: - 1. Falling margins and hence lower profits with projected EPS to be ~ 10% lower this year at around 13.5p vs 15p This was reflected in H1 results. So current P/E around 11. 2. In common with other retailers recently listed on the market e.g. CARD the intangible/goodwill figure on the balance sheet is large. In this case intangibles/goodwill = �990M with net assets stated as �883M. If anything CARD has an even worse balance sheet with just 10% of their total assets listed as tangible assets. I suppose the bigger question is why the market chose to ignore the second of these points for 3 years or why it chose to price PETS at 20x earnings for so long? #rogue and fickle market.

Transfer financing to Takeda's acquisition 3 trillion yen including Mitsui Sumitomo and Mitsubishi UFJ With May 3, 2018 Nikkei Shimbun Morning Paper Takeda Pharmaceutical Industry, which entered final adjustment for the acquisition of Ireland Pharmaceutical leading giant Shire, said that Sumitomo Mitsui Banking Corp. and Mitsubishi UFJ Bank, etc. will carry out the loan, said on Tuesday. Loan amount including US and Bank is expected to be 3 trillion yen scale. If realized it will be the largest project as co-financing with Japanese banks. The commitment of large-scale loans by major banks will be a boost to Takeda, which will proceed with the acquisition negotiations. A commitment letter to clarify the willingness to lend before concluding a loan agreement ...

Cobus stated Baberton Mines would produce 50,000oz in H2. I assume this includes BTRP hence my 100K estimate for Baberton including BTRP. Yes gold could drop to $1200 but the weakening rand would help mitigate that and who knows gold could hit $1400 pushing projected EPS closer to 3p. New production from Egoli and Sheba would also be low cost and push profits higher. Last time the company made a healthy profit was in 2013 when gross profit hit �56M; hoping for a similar number in 2018-19.

Something is going on. Clearly. 10% up in 2 days.

I calculate Evander cost the company 5M GBP in H1 alone. That's half the EPS for H1. With a bit of luck full year EPS of 2.5p is achievable here with Elikhulu onstream and a gold price around $1300. That puts the shares on a P/E less than 3. £50-60M annual profit for 2018-19 would be serious cashflow and negate any need for a placing. Even at 10x projected earnings the SP here should be nearer 25p not 7p!!!

Surprised no comments here after such an important RNS. So as expected really Evander will be shut/suspended this month. Redundancy money will be paid to the Evander miners. Higher than I expected to be honest at approx �9M . Evander was loss-making though so this move does make sense and should boost profits. The Elikhulu project will start production in August 2018 and, combined with a smaller existing tailings retreatment operation at Evander, deliver 70,000oz of gold at a cost of less than $700/oz. **These two operations alone should produce $42M in profit/�30M GBP** I make Baberton and BTRP as producing approx 100Koz/year and potentially producing another �30M in profit at a gold price of $1300/oz. Gross profit of �60M would give EPS of 2.7p which makes the current P/E just 2.7 What sort of figures are others calculating here? Thoughts welcome. BTW I do not expect any dividend at year end this year although special dividend possible I suppose once Elikhulu starts up in August.

However, when it comes to his own company, Wiley said it is "hard to say" whether Amryt will be one of those companies gobbled up by a global drugmaker. "We are building a sustainable growth business focused on rare and orphan diseases, and we see ourselves building that and growing that business through acquisitions and organically ourselves. We�re focused on delivering on that for our shareholders," Wiley said ************************************************** Note shareholders not stakeholders

Well rxdav no one can accuse the stock of being expensive given it is still barely trading at just 10x earnings. At 180p the P/E is still only 13.

Trading at 1 year lows. FH treatment alone worth 20p+ Placing was done at 20p also. Always chance of M&A also EB treatment could be game changer

Ex-dividend 17th May 6p

Seems to be trading well below historical P/E rating

?cause

We are still 'only' 32% down from the 3 year average share price.

People seem to have forgotten the �2Bn+ potential return from the nuclear plant sale.

Poor GDP in Q1 means interest rate rise unlikely next month.

There is a nice bowl shaped chart forming here and I see no reason why the SP can not get back to 180p+ in time. Even at 180p the P/E is only 13 and the yield 5%. M&A is also a possibility. The SP has been played big time and someone was loading up at 110p.

Trades are misreported all the time. Even multi million ones. Could even have been a buy. On a positive ex dividend just 2 weeks away now and it looks like we should be nearer 140-150p by then.